Geneuro Logo

Geneuro

Develops therapies for neurological and autoimmune diseases by targeting HERVs.

GEM | PA

Overview

Corporate Details

ISIN(s):
CH0308403085
LEI:
213800FUJCKXO9LK3444
Country:
Switzerland
Address:
chemin du Pré-Fleuri 3, 1228 Plan-les-Ouates

Description

Geneuro is a clinical-stage biopharmaceutical company developing treatments for neurological and autoimmune diseases. The company's approach focuses on neutralizing pathogenic proteins expressed by human endogenous retroviruses (HERVs), which are believed to be causal factors in the progression of certain diseases. Its primary areas of development include conditions such as multiple sclerosis (MS) and post-COVID syndrome (long-COVID). Geneuro's lead product candidate, temelimab, is a monoclonal antibody designed to target and neutralize a specific HERV envelope protein. This strategy aims to block the inflammatory and neurodegenerative processes associated with these diseases, representing a precision medicine approach to treatment.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-26 18:36
Inside Information / Other news releases
English 212.6 KB
2025-09-26 18:36
Informations privilégiées / Autres communiqués
French 215.2 KB
2025-06-30 19:37
Inside Information / Other news releases
English 224.5 KB
2025-06-30 19:37
Informations privilégiées / Autres communiqués
French 753.1 KB
2025-06-12 22:42
Inside Information / Other news releases
English 204.9 KB
2025-06-12 22:42
Informations privilégiées / Autres communiqués
French 203.8 KB
2025-06-10 18:24
Informations privilégiées / Autres communiqués
French 207.4 KB
2025-06-10 18:24
Inside Information / Other news releases
English 209.5 KB
2025-05-27 18:00
Inside Information / Other news releases
English 162.5 KB
2025-05-27 18:00
Informations privilégiées / Autres communiqués
French 187.1 KB
2025-05-12 18:36
Inside Information / Other news releases
English 481.8 KB
2025-05-12 18:36
Informations privilégiées / Autres communiqués
French 669.5 KB

Automate Your Workflow. Get a real-time feed of all Geneuro filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Geneuro

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Geneuro via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.